Sign In
Buy LPTX
$0.690
+0 (+0%)
At Close: Jun 23, 2026
Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks
10:36am, Wednesday, 20'th Mar 2024
Leap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings e
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
07:00am, Monday, 18'th Mar 2024
CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financi
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium
05:05pm, Tuesday, 16'th Jan 2024
30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus bevacizumab and chemotherapy Subgroup analysis reveals greatest benefit in left-sided tumors, particularly rec
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
07:00am, Wednesday, 03'rd Jan 2024
CAMBRIDGE, Mass. , Jan. 3, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Do
CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that e
CAMBRIDGE, Mass. , Dec. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that t
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference
07:00am, Tuesday, 21'st Nov 2023
CAMBRIDGE, Mass. , Nov. 21, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Do
Leap Therapeutics Reports Third Quarter 2023 Financial Results
07:00am, Monday, 13'th Nov 2023
CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financi
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
12:22pm, Tuesday, 24'th Oct 2023
NEW YORK, NY, October 24, 2023 – The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopoliti
Leap Therapeutics to Participate at Upcoming Investor Conferences
07:00am, Tuesday, 05'th Sep 2023
CAMBRIDGE, Mass. , Sept. 5, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Do
Leap Therapeutics Reports Second Quarter 2023 Financial Results
07:00am, Monday, 14'th Aug 2023
CAMBRIDGE, Mass. , Aug, 14, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financia
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients
07:00am, Wednesday, 12'th Jul 2023
CAMBRIDGE, Mass., July 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, ba
19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in overal
3 Hot Penny Stocks To Watch Under $1, Time To Buy?
03:25pm, Thursday, 18'th May 2023
Penny stocks under $1 to watch this week. The post 3 Hot Penny Stocks To Watch Under $1, Time To Buy?
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations
11:51pm, Monday, 30'th Jan 2023
NEW YORK , Jan. 30, 2023 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights
